Genelux (GNLX) Amortizatization of Intangibles (2022 - 2026)
Genelux (GNLX) posted quarterly Amortizatization of Intangibles of $70000.0 for Q1 2026, down 50.0% year-over-year from $140000.0 in Q1 2025, and up 125.81% quarter-over-quarter from $31000.0 in Q3 2025.
Genelux (GNLX) Amortizatization of Intangibles (2022 - 2026) Analysis & Trends
Genelux's Amortizatization of Intangibles history runs 5 years deep, the most recent figure standing at $70000.0 for Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 50.0% year-over-year to $70000.0; the TTM figure through Mar 2026 stood at $258000.0 (down 62.93% YoY), while the FY2023 annual figure was $62000.0, down 75.97% from the prior year.
- Amortizatization of Intangibles for Q1 2026 stood at $70000.0, up from $31000.0 in the prior quarter.
- The five-year high for Amortizatization of Intangibles was $649000.0 in Q1 2023, with the low at -$587000.0 in Q4 2023.
- The 5-year median for Amortizatization of Intangibles is $90000.0 (2022), against an average of $90333.3.
- Peak annual rise in Amortizatization of Intangibles reached 1224.49% in 2023, while the deepest fall reached 633.64% in 2023.
- Genelux's Amortizatization of Intangibles stood at $110000.0 in 2022, then slumped by 633.64% to -$587000.0 in 2023, then jumped by 142.93% to $252000.0 in 2024, then tumbled by 87.7% to $31000.0 in 2025, then soared by 125.81% to $70000.0 in 2026.
- Business Quant data shows GNLX's Amortizatization of Intangibles at $70000.0 in Q1 2026, $31000.0 in Q3 2025, and $17000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Genelux | 119.87 Mn | 119.87 Mn | - | 89,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 70,000.00 |
| Mar 31, 2026 | 70,000.00 |
| Sep 30, 2025 | 31,000.00 |
| Sep 30, 2025 | 31,000.00 |
| Jun 30, 2025 | 17,000.00 |
| Jun 30, 2025 | 17,000.00 |
| Mar 31, 2025 | 140,000.00 |
| Mar 31, 2025 | 140,000.00 |
| Sep 30, 2024 | 252,000.00 |
| Sep 30, 2024 | 252,000.00 |
| Jun 30, 2024 | 153,000.00 |
| Jun 30, 2024 | 153,000.00 |
| Mar 31, 2024 | 151,000.00 |
| Mar 31, 2024 | 151,000.00 |
| Dec 31, 2023 | -587,000.00 |
| Dec 31, 2023 | -587,000.00 |
| Mar 31, 2023 | 649,000.00 |
| Mar 31, 2023 | 649,000.00 |
| Dec 31, 2022 | 110,000.00 |
| Dec 31, 2022 | 110,000.00 |